LOXL2 and familial pancreatic carcinoma: In the current study, four pancreatic cancer biomarker candidates (SYCN, REG1B, AGR2 and LOXL2) delineated through our previous integrated proteomics analysis of cell line conditioned media and pancreatic juice [13], were validated in two sample sets of serum/plasma containing a total of 432 samples.